Dr. Daniel Ives — Founder and Chief Executive Officer — Shift bioscience Ltd.
Driver Clocks and Longevity – Dissecting the true functional \”drivers\” of aging phenotypes – Dr. Daniel Ives, Ph.D. Founder and CEO – Shift Bioscience Ltd.
Dr. Daniel Ives, Ph.D. is Founder and CEO of Shift Bioscience Ltd. (https://shiftbioscience.com), a biotech company making drugs for cellular rejuvenation in humans through the application of machine-learning ‘driver’ clocks to cellular reprogramming, and is the scientific founder who first discovered the gene shifting targets upon which the Shift drug discovery platform is based.
Dr. Ives received his degree in biochemistry from Imperial College and earned his PhD at the MRC Mitochondrial Biology Unit, Cambridge in 2013. His postdoctoral research was conducted under Ian Holt, at the National Institute of Medical Research, Mill Hill (now part of the Crick Institute), pursuing damage removal strategies for mitochondrial mutations.
In 2016, Dr. Ives quit the Crick Institute to found Shift Bioscience, a company that commercializes mitochondrial-targeted drugs for age-related diseases. Shift Bioscience uses novel ageing biomarkers, CRISPR screenings, and other tools in order to identify true functional ‘drivers of ageing phenotypes.
Source:
